Navigation Links
China Biologic Products Enters Into Agreement to Acquire 35% Interest in Xi'an Huitian Blood Products Co., Ltd. and Introduces Preliminary Guidance for 2009
Date:10/16/2008

ian. China Biologic believes that it will be able to secure the large majority of the financing required for the two acquisitions from domestic bank facilities and available cash resources. Taibang's other shareholder, Shandong Institute of Biological Products, who owns approximately 17% of Taibang, contractually agreed with China Biologic's wholly-owned subsidiary, Logic Express, to allocate to Logic Express all of the economic benefits (i.e., revenues and net income) and burdens (i.e., expenses, losses and liabilities) of the 35% interest in Huitian that will be acquired by Taibang. Shandong Institute of Biological Products will not contribute any amounts toward the financing of Huitian. The remaining 65% interest in Huitian is owned by Shaanxi Power Construction Group Corporation ("SPCGC") in China, a power construction company in Shaanxi Province. According to the terms of the contract, both parties have agreed not to sell their equity interests in Huitian to a third party within the next five years, giving each other the right of first refusal thereafter. China Biologic plans to expand Huitian's plasma collection capacity in Shaanxi Province and eventually acquire the remaining interest from SPCGC if such opportunity exists.

Company Updates Business Outlook

Management expects that the acquisitions of Dalin (Qianfeng) and Huitian will accelerate the Company's geographical expansion, diversify its customer base, enhance its technological capabilities or competitive advantages and serve to fulfill its planned expansion into the leading biopharmaceutical company in China. China Biologic has targeted combined revenue for 2008 to be in the range of $48 million to $50 million and combined net income to be between $9 million to $10 million, including only a portion of the 4th quarter operations from the two acquisitions. Assuming the full year consolidation of the two acquisitions, management estimates revenues for 2009 will be in the range of $90 million
'/>"/>

SOURCE China Biologic Products, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
4. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
5. China Technology Announces New Chief Financial Officer
6. China Medical Technologies Reports First Quarter Financial Results
7. China Medical Technologies to Participate in Credit Suisses 2007 Asian Technology Conference
8. China Technology Announces Entry to the Solar Energy Sector
9. China Sky One Medical Receives $1.5 Million Government Grant to Further Develop Six New Cancer Products
10. Kiwa Bio-Tech Named Recommended Brand by the China Green Food Association
11. China Kangtai Cactus Biotech, Inc. Announces Plans for New Product Launch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... April 27, 2015 DryLet, LLC ... in applications such as animal waste reduction, bioremediation, ... reduction in wastewater treatment plants and restaurant kitchen ... at the Texas Commission on Environmental Quality (TCEQ) ... Austin, Texas. , The company will highlight three ...
(Date:4/27/2015)...  Together with its customers, Elekta raised EUR 30,575 ... Barcelona . The funds will be donated ... to improve cancer care, specifically radiation oncology care, around ... patient should be denied potentially life-saving treatment simply because ... hospitals and clinics around the world to take care ...
(Date:4/24/2015)... Tempe, AZ (PRWEB) April 24, 2015 ... Arizona State University (ASU) have entered into an agreement ... , A memorandum of agreement signed by the universities ... learning, student success and other services particularly, though not ... , “We have complementary strengths and a similar set ...
(Date:4/24/2015)... , April 24, 2015  Pfenex Inc. (NYSE MKT: ... of biosimilar therapeutics including high value and difficult to ... public offering of 6,000,000 shares of its common stock ... share. Of the shares being offered, 2,610,000 are being ... being offered by existing stockholders. Pfenex will not receive ...
Breaking Biology Technology:DryLet to Showcase Multiple Products at Texas Commission on Environmental Quality Trade Fair and Conference May 5-6 in Austin, Texas 2Elekta helps raise $33,000 to bring radiation treatment to developing countries 2Elekta helps raise $33,000 to bring radiation treatment to developing countries 3South Dakota Mines, Arizona State University Pave Way for Cooperative Research 2Pfenex Inc. Announces Pricing Of Follow-on Offering 2
... into the human brain to understand its functions in ... illness — has long been a challenge for researchers. ... and sensors that can damage tissue while only reading ... Jonathan Viventi , assistant professor at ...
... Sequenom, Inc. (NASDAQ: SQNM ), a life ... it will host an Investor and Analyst Day at NASDAQ ... 2:00 to 5:00 pm ET. Key members of the company,s ... specifically focusing on the recent commercial launch of the MaterniT21 ...
... Calif., Nov. 14, 2011 VIVUS, Inc. (NASDAQ: ... TA-314, a phase 3 long-term safety and efficacy study ... erectile dysfunction (ED), was presented over the weekend at ... Meeting in Las Vegas, NV.  Andrew R. McCullough, MD, ...
Cached Biology Technology:Flexible Sensors Offer Unprecedented View of Brain Activity During Epileptic Seizures 2Flexible Sensors Offer Unprecedented View of Brain Activity During Epileptic Seizures 3Flexible Sensors Offer Unprecedented View of Brain Activity During Epileptic Seizures 4Sequenom to Host Analyst Day on Monday, November 14, 2011 215-Minute Data From Phase 3 Study of Avanafil Featured as a Late Breaking Abstract at SMSNA Annual Meeting 215-Minute Data From Phase 3 Study of Avanafil Featured as a Late Breaking Abstract at SMSNA Annual Meeting 315-Minute Data From Phase 3 Study of Avanafil Featured as a Late Breaking Abstract at SMSNA Annual Meeting 4
(Date:4/2/2015)... 2015 At its 2015 ACMG Annual Clinical ... , the American College of Medical Genetics and Genomics ... its Board.  Members of the ACMG Board of Directors ... and advancing its policies and programs. ACMG is the ... "It,s an eventful time in medical genetics and genomics.  ...
(Date:4/1/2015)... , Apr. 1, 2015  NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market, ... Wocket smart wallets is underway to early access pre-order ... group includes usage at retail outlets including Walmart, Target, ... Users report Wocket was accepted at all outlets and ...
(Date:3/31/2015)... NEW YORK , March 31, 2015   ... announced the launch of the Post-Surgical Pain Management TRACKER, ... data products tracking usage trends in the medical device ... monthly access to data including treatment volumes, market share, ... manage the pain associated with joint surgery. ...
Breaking Biology News(10 mins):American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3
... When a foreign object such as a catheter enters the ... into a slick coating a biofilm that is ... cannot be defeated by a basic approach of conventional means. ... reveals the key players in the network and how they ...
... 2010 China PharmaHub Corp. (OTC Bulletin Board: ... agreement to be a distributor for Integrated Biometrics ("IB"), ...  PharmaHub will have the exclusive distribution rights in China, ... to sell IB products to customers in the Pharmaceutical, ...
... soldiers in the battlefield healthy, the U.S. Army is exploring ... Current techniques for analyzing water in the field can take ... Lipkens of Western New England College in Springfield, Massachusetts and ... They are working on an alternative technology that uses sound ...
Cached Biology News:Research provides new leads in the case against drug-resistant biofilms 2China PharmaHub Signs Distribution Agreement with Integrated Biometrics 2China PharmaHub Signs Distribution Agreement with Integrated Biometrics 3
Each bottle contains: Bromophenol Blue 0.25% w/v , Xylene Cyanol FF 0.25%, Glycerol solution 30% w/v...
Ideally suited for resolving DNA and RNA 10-1000 bases especially PCR products ranging from 100-1000 bp. Gelling temp. (4%) 27C Melting temperature 65C. EEO: 0.10 Rnase/Dnase: none detected...
XEDAR Antibody...
Xanthine Oxidase (Bovine Buttermilk). Monospecific by IEP. Some cross reactivity with Xanthine Oxidase of other species and tissues may occur....
Biology Products: